Plenary Session - inactive due to federal service
420 episodes — Page 3 of 9
5.26 - Hawaii Oncology Association Keynote Lecture
ELecture I gave this weekend in Hawaii to the Medical Oncology Association; One of the best audiences I've had
5.25 - Neurosurgery Grand Rounds by Vinay Prasad
EI give Grand Rounds to UCSF Neurosurgery on how to read and interpret Neurosurgery Studies (Video and slides coming soon to YouTube) Also I discuss Bob Califf's Promotion of Paxlovid
5.24 Vlad Kogan is back to discuss Kids Test Scores
ELearning Loss is Devastating; Here are the data and what it means
5.24 - Gerald Hsu MD PhD UCSF Heme Onc Program Director
ELearn about UCSF Hematology Oncology Program with Dr. Gerald Hsu, MD PhD Malignant Heme and Program Director
5.23 - Subclinical Myocarditis
EA new study from Switzerland confirms the rate of subclinical myocarditis
5.23 - ID Ethicist joins me for a 6th discussion of COVID19 policy
ELONG COVID, Vaccines, Paxlovid and More
5.22 NordICC trial interview with PI Michael Bretthauer - Offer but don't Nudge
Ediscuss NordICC with the trial PI Power calc specified 50% non-adherence ADR is on par with US studies from the time Colo quality good Perf rate lower than US! How does he counsel individuals & governments What he thinks of USPSTF
5.21 Science Mag Editor Condemns Ladapo But Silent About Jha
EA double standard to condemn data with limitations, based on political party, will destroy medicine. We will back to oncology soon, but this is important
5.20 The Great Colonoscopy Debate
ECifu, Mandrola and Prasad fight about colonoscopy
5.19 - NEJM's first ever RCT of Colonoscopy-- Explained
EI break down the history and data for the first ever randomized trial of colonoscopy, appearing in NEJM on Oct 9, 2022
5.18 Lecture to Heme Onc Fellows - POLO; Javelin 100 bladder
EPolo Javelin 100 bladder Crossover Control arms How to read and keep up with the literature
5.17 - The State Of Precision Oncology
EInvited Lecture to Cancer Center Directors
5.16 - Aaron Goodman UCSD
EI travel to UCSD to interview Dr. Goodman about myeloma, celebrity oncology culture, his career, education, patient care, choosing a specialty and more.
5.15 - How To Apply For And Get Your Perfect First Job
EBased on listener questions, I discuss how to apply for and get your first job.
Unspoken Rules of Oncology - Malignant BC Part 6
ET.O. joins me for the missing episode. These are the unspoken rules of Oncology; We dive deeper into Malignant Book Club.
Malignant Book Club - Episode 7 - famous trials
ETimothee Olivier joins me for the 7th installment of our book-club We cover famous trials in oncology
5.12 - Academics Vs Industry - A.Goodman S.Loghavi D.Steensma V.P.
EHow do careers vary between the academy and industry? We have a panel of the best: Sanam Loghavi from MD Anderson, Aaron Goodman UCSD, and David Steensma Novartis (formerly Farber/ Mayo) and VP #Real talk
5.11 - Malignant Book Club - Part 5
ETimothee Olivier joinrs me as we explore part 3 of the book Crossover, sample size, observational vs RCTs
5.10 - Adam Cifu on clinical excellence
EAdam Cifu is here to discuss clinical excellence and his new podcast
5.09 - Malignant Book Club Part 4
ET.O. joins me to grill me on the rest of Financial Conflict of Interest and Precision Oncology. We discuss the need for randomization, and when it can be omitted. A must listen for Oncology Fans.
5.08 - LaceWing RCT Phase 3 Blood - Spin Cycle
EVP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more
5.07 - Plenary Session Alps Edition
ETimothee Olivier joins me to discuss recent papers: IMPOWER10 Checkmate 816 Path CR/ EFS/ Surrogates Drug Dosing, cGCSF rules and more Bread and butter oncology
5.06 - POLO trial now has OS results - OMG
EThe POLO trial, which we first broke on PS Season 1- is back with null OS results. But the trial authors enter the spin cycle. VP goes line by line.
5.05 - Citations, Metrics, Rankings in Oncology & Medicine
EVP explains H index, total cites, papers, US News and World Report rankings and how evaluates researchers and doctors.
5.04 - Echelon 1 reports OS benefit - But does it add up?
EVP addresses what to do you if you get an idea from listening to the show, and deconstructs ECHELON-1. Instead of listening we highly recommend you watch the video on YouTube with graphics. This is worth the watch.
5.03 - VPs Grand Rounds Lecture - Evidence Based Medicine - Will it Survive?
EHow to think about when and how to do RCTs? What are the limitations to observational studies? Smoking. Parachutes. Dostarlimab. Guarantee Time Bias. Confounding. Multiple Hypothesis testing and more
5.02 - Listener Questions - Cancer & Evidence Philosophy - What this Pod Offers
EI make the case why this podcast should be your go to for Med, Onc & Policy. I describe my philosophy of Evidence, Empiricism, and show how this connects to many oncology studies. I answer a bunch of Listener Questions
5.01 - How To Read Randomized Trials In Cancer
EHow to read randomized trials in cancer medicine. Phase 2 vs 3, control arm, crossover, post protocol, censoring (the basics), and how law professors and medical professors are different and why it matters.
Lies and Exaggerations about Kids Vaccines < 5 years Old is Bad Public Health
ELies and Exaggerations about Kids Vaccine I give examples, and show why they are lies
Enact Trial - Enza vs Active Surveillance in Localized Prostate Cancer
EWhat happens when you treat people with $168,000 a year medicine when most of them will never need treatment, and all of them don't need treatment now
Kids Vaccine For Under 5 years Old
EI take a deep dive into the data for the mRNA vaccines for kids under 5 years olds
H. Jack West; Lung Cancer; Podcasting; TeleHealth: PACIFIC; ADAURA;CM816: KN189
EI sit down with H Jack West. City of Hope. Thoracic Oncology and we have a long discussion about trials; staging; PDL1 thresholds; Driver mutations and post protocol care; ADAURA; Adjuvant; & More
QuANTUM - Quizartinib Front Line - Ethics of Global Trials
EI discuss the timeline of Ratify and Quantum. Was this an ethical trial? Is it sufficient to say a trial is ethical because 50% of participants get something?
4.67 Teclistimab for R/R Multiple Myeloma
EThe drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates
4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??
EAre the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??
4.65 DESTINY BREAST 04 - A complex trial to deconstruct
EMy take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low
4.64 - DETERMINATION - Should we still use transplant Myeloma?
EI break down Richardson, et al. NEJM DETERMINATION Transplanters are determined to keep going, should they be? Watch the videos b/c I have lots of great visuals My ASCO Coverage continues
4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer
EThe second paper from #ASCO2022 #ASCO22 that I break down This is one of the most technical papers I breakdown on the channel CT DNA used to omit chemo in Stage II colon cancer Read the book Malignant if you learn from this Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU
4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
EContinuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/

4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis
EI am joined by Dr. Katie Sharff, infectious disease doc, to discuss two of her papers on myocarditis after COVID-19 vaccination. https://doi.org/10.1016/j.amjcard.2022.02.039 https://doi.org/10.1101/2021.12.21.21268209
4.60 - NEW JCO paper - AML, EFS, CR, CRi, and Surrogate validation - FDA & Methods
EI get back to my roots; I explain surrogate validation and a new JCO paper from the FDA authors on EFS and OS in AML. You won't want to miss it
4.59 - How to be a better reader of case control studies
EIn this episode I dissect a test negative case control trial; I talk about a famous pancreas cancer study and I revisit the failure of Myeloma trialists
4.58 - Myeloma is a broken field - New BLOOD Paper!
EI am joined by Manni Mohyuddin to talk about How I treat frontline transplant eligible myeloma. Vinay Prasad makes the case the entire field of myeloma is corrupt and broken.
4.57 - COVID19 and the Failures of Public Health w/ Leslie Bienen
EI join Dr. Bienen in person to discuss COVID19 and failures in public health
4.56 - Fifth Installment of the brilliant Zeb Jamrozik
EID ethicist, and brilliant COVID19 commenter
4.55 - Compilation Of Recent Covid Monologues
EThis is a compilation of the last week and half of monologues by VP on his Youtube Channel about COVID19 policy
4.54 - Eric Collisson Professor, GI Oncologist, Physician Scientist
EI talk to UCSF Professor Eric Collison about his lab, grant writing, the physician scientist life, cancer, and a doctors duty.
4.53 John Ioannidis lectures the VKPrasad Lab about COVID19
EA brilliant talk by one of the most brilliant scientists alive; JPAI lectures VKPrasad lab on all things COVID19; When does the pandemic end? What are the lessons?
4.52 Vinay Prasad Gives a Lecture on COVID19 to a General Audience
EListen in as I give an unscripted lecture to a general audience about COVID-19; What we got right and wrong these last 2+ years.
4.51 - Vinay Prasad is Interviewed by Kristina Jenei About Academic Medicine
EKristina Jenei becomes the 4th guest host and flips the tables on me, interviewing me about academic medicine and more...